

Tian Yu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4332404/publications.pdf>

Version: 2024-02-01

27
papers

1,564
citations

567281

15
h-index

552781

26
g-index

27
all docs

27
docs citations

27
times ranked

2996
citing authors

#	ARTICLE	IF	CITATIONS
1	Advances in nucleic acid amplification techniques (NAATs): COVID-19 point-of-care diagnostics as an example. <i>Biosensors and Bioelectronics</i> , 2022, 206, 114109.	10.1	82
2	Retinoic acid-induced autoantigen-specific type 1 regulatory T cells suppress autoimmunity. <i>EMBO Reports</i> , 2019, 20, .	4.5	24
3	A Study of Immune Function Improvement Induced by Ganoderma Lucidum Alkaloid in Mice. , 2018, , .		0
4	The atypical chemokine receptor-2 does not alter corneal graft survival but regulates early stage of corneal graft-induced lymphangiogenesis. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2018, 256, 1875-1882.	1.9	4
5	In silico identification of potent small molecule inhibitors targeting epidermal growth factor receptor 1. <i>Journal of Cancer Research and Therapeutics</i> , 2018, 14, 18-23.	0.9	5
6	AUC-Guided Vancomycin Dosing in Adolescent Patients With Suspected Sepsis. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 77-84.	2.0	25
7	Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus. <i>Clinical Pharmacokinetics</i> , 2017, 56, 107-125.	3.5	8
8	Clinical pharmacokinetics of magnesium sulfate in the treatment of children with severe acute asthma. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 325-331.	1.9	32
9	Renal Function Descriptors in Neonates: Which Creatinine-Based Formula Best Describes Vancomycin Clearance?. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 528-540.	2.0	8
10	Optimizing the use of intravenous magnesium sulfate for acute asthma treatment in children. <i>Pediatric Pulmonology</i> , 2016, 51, 1414-1421.	2.0	17
11	Pregnancy-induced changes in the pharmacokinetics of caffeine and its metabolites. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 590-596.	2.0	45
12	Incorporating pharmacodynamic considerations into caffeine therapeutic drug monitoring in preterm neonates. <i>BMC Pharmacology & Toxicology</i> , 2016, 17, 22.	2.4	14
13	Herbal medicines: challenges in the modern world. Part 3. China and Japan. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1225-1233.	3.1	50
14	Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 731-746.	4.4	20
15	Determination of Optimal Amikacin Dosing Regimens for Pediatric Patients With Burn Wound Sepsis. <i>Journal of Burn Care and Research</i> , 2015, 36, e244-e252.	0.4	27
16	Evaluation of Vancomycin Use in Late-Onset Neonatal Sepsis Using the Area Under the Concentration-Time Curve to the Minimum Inhibitory Concentration ≥ 400 Target. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 756-765.	2.0	21
17	Deficiency of Lipoprotein Lipase in Neurons Decreases AMPA Receptor Phosphorylation and Leads to Neurobehavioral Abnormalities in Mice. <i>PLoS ONE</i> , 2015, 10, e0135113.	2.5	13
18	Pharmacokinetic considerations in the use of antivirals in neonates. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1861-1878.	3.3	3

#	ARTICLE	IF	CITATIONS
19	Optimal design in pediatric pharmacokinetic and pharmacodynamic clinical studies. <i>Paediatric Anaesthesia</i> , 2015, 25, 222-230.	1.1	25
20	Pharmacokinetic modeling of therapies for systemic lupus erythematosus. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 587-603.	3.1	4
21	Evolution of interventional vancomycin trials in light of new antibiotic development in the USA, 1999-2012. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 215-222.	2.5	6
22	Use of Methylxanthine Therapies for the Treatment and Prevention of Apnea of Prematurity. <i>Paediatric Drugs</i> , 2014, 16, 169-177.	3.1	47
23	Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 1371-1388.	4.4	12
24	Size and surface charge significantly influence the toxicity of silica and dendritic nanoparticles. <i>Nanotoxicology</i> , 2012, 6, 713-723.	3.0	145
25	In vivo biodistribution and pharmacokinetics of silica nanoparticles as a function of geometry, porosity and surface characteristics. <i>Journal of Controlled Release</i> , 2012, 163, 46-54.	9.9	164
26	Influence of Geometry, Porosity, and Surface Characteristics of Silica Nanoparticles on Acute Toxicity: Their Vasculature Effect and Tolerance Threshold. <i>ACS Nano</i> , 2012, 6, 2289-2301.	14.6	186
27	Impact of Silica Nanoparticle Design on Cellular Toxicity and Hemolytic Activity. <i>ACS Nano</i> , 2011, 5, 5717-5728.	14.6	577